Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification
about
Bromocriptine versus levodopa in early Parkinson's diseaseNeurotransmitters in hiccupsTreatment of advanced Parkinson's diseaseChronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.Parkinson's disease--levodopa complications.Brittle Dyskinesia Following STN but not GPi Deep Brain Stimulation.Convergent evidence for abnormal striatal synaptic plasticity in dystonia.Pharmacotherapy for advanced Parkinson's disease.Clinical spectrum of levodopa-induced complications.Assessing Motor Fluctuations in Parkinson's Disease Patients Based on a Single Inertial SensorPeriodontal health and caries prevalence evaluation in patients affected by Parkinson's diseaseLevodopa, motor fluctuations and dyskinesia in Parkinson's disease.Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesiaTreatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Continuous dopaminergic stimulation and novel formulations of dopamine agonists.Apomorphine hydrochloride for the treatment of Parkinson's disease.Mechanisms for pattern specificity of deep-brain stimulation in Parkinson's disease.Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Quantification of dyskinesia in Parkinson's disease: validation of a novel instrumental method.Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.Levodopa-induced ocular dyskinesias in Parkinson's disease.Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys.Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Striatal Gαolf/cAMP Signal-Dependent Mechanism to Generate Levodopa-Induced Dyskinesia in Parkinson's Disease.Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.Subthalamic activity during diphasic dyskinesias in Parkinson's disease.Subthalamic oscillatory activity in parkinsonian patients with off-period dystonia.Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.Motor Complications of Dopaminergic Medications in Parkinson's Disease.Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.
P2860
Q24243591-049C3C1B-F5F7-4A55-A1CA-04DFD1C1BBCAQ28076455-055D2CD1-18C4-437D-A39D-DA599FF1E535Q30476968-EE829487-A9AA-49DF-BB69-9467C9427872Q30484170-0C6D62FD-A2A8-4795-A4F6-BAC58E892C43Q33714114-F4204F18-CBE0-4832-9717-A8F713A775E2Q33728971-08AC454B-0CA9-410D-9249-DCA9A96D65ACQ33756951-B16C24A2-3634-48EA-8DFC-5808DBF6081CQ33821336-3E4B7A65-EA39-4A37-925B-6ED0C0B03DDBQ34452721-33F2E93C-1B44-4D15-BCF6-E9B1FFD1ECF2Q36226593-5B4FD91D-1FE1-4224-8F98-989D1CCAA733Q36516071-E79202FD-53C1-4883-AC0C-5F4B3B1CAADEQ36573882-B9ED3EBF-2E6A-4F33-9435-3D753B40040DQ37277039-D4F9F4DB-7116-4302-A9DB-AC4804FEFFB7Q37506507-6E21E5BE-C5BE-442D-BC84-A9A679A91F1CQ37874192-FBC1EFE2-2FE3-4310-B45B-5C0B10A22D39Q38513905-954404DC-C647-4AC4-A20F-D4A9014871D0Q41433072-27603999-B169-42F2-B2A2-F7DD2AC485EDQ41626118-34C29054-9E7F-4497-89A0-B2B76C82C3C3Q41645312-EEEF2798-FFCF-4161-9130-72C7B83A993BQ41691617-DC91A55F-D910-45D7-9423-D67D70CF622CQ41701370-A52C0AA7-9B77-4706-BD41-CFC5A5CF2075Q42164140-3CC2E70A-9D14-498B-B054-96B22CE7D454Q42492136-C838A15D-438A-4F61-A609-E45936A3F62FQ43570440-FEE79185-C193-4F91-8152-DDB4855C6294Q43693346-AB738303-7ED2-4B27-B879-3BD0B788153AQ43693354-1ABED90C-1CCD-4963-AD40-2F16EDBDCD26Q44165234-55FC0C82-EB22-4B56-8F98-14CB19673C64Q44639804-7C160040-918C-4DF1-987D-A6427F477F51Q45985296-9D66A08B-E501-4F2A-B43E-AA06CC565494Q46354756-7DF6BFBB-463C-4C1B-92BA-1D1B59A9F078Q47105024-3416260B-DB90-40A5-9750-84D9D67AB093Q47289908-98EFBF59-0105-479B-9D79-21449A26A07AQ48457225-5A8BFB91-79E2-4F94-8D94-EF3FDF3C726DQ48489632-797846E3-A32B-4FD8-A457-3F49179B938CQ48829185-433FC62D-A67C-495B-A945-DD7D40961F48Q55279095-BC86E02E-A072-4461-ABA1-A98D643AA76EQ55431534-235CEE52-9995-4C01-9CA8-6FE2449D17A4
P2860
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification
description
1992 nî lūn-bûn
@nan
1992 թուականին հրատարակուած գիտական յօդուած
@hyw
1992 թվականին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Levodopa-induced dyskinesias i ...... pharmacological classification
@ast
Levodopa-induced dyskinesias i ...... pharmacological classification
@en
Levodopa-induced dyskinesias i ...... pharmacological classification
@nl
type
label
Levodopa-induced dyskinesias i ...... pharmacological classification
@ast
Levodopa-induced dyskinesias i ...... pharmacological classification
@en
Levodopa-induced dyskinesias i ...... pharmacological classification
@nl
prefLabel
Levodopa-induced dyskinesias i ...... pharmacological classification
@ast
Levodopa-induced dyskinesias i ...... pharmacological classification
@en
Levodopa-induced dyskinesias i ...... pharmacological classification
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Levodopa-induced dyskinesias i ...... pharmacological classification
@en
P2093
J Vaamonde
M R Luquin
O Gershanik
O Scipioni
P2860
P304
P3181
P356
10.1002/MDS.870070204
P407
P577
1992-01-01T00:00:00Z